Analysis of immune activation and clinical events in acute infectious mononucleosis

Journal of Infectious Diseases

Volumn 190, Issue 1, 2004, Pages 63-71

  Williams, Hilary ^a   Macsween, Karen ^a,e   McAulay, Karen ^a   Higgins, Craig ^c   Harrison, Nadine ^b   Swerdlow, Anthony ^c   Britton, Kate ^a,d   Crawford, Dorothy ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d WESTERN GENERAL HOSPITAL   (United Kingdom)

^e ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD150 ANTIGEN; SIGNALING LYMPHOCYTE ACTIVATION MOLECULE ASSOCIATED PROTEIN;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN CELL; INFECTIOUS MONONUCLEOSIS; MALE; PRIORITY JOURNAL; SORE THROAT; T LYMPHOCYTE ACTIVATION; UPREGULATION; VIRUS LOAD;

ACUTE DISEASE; ADOLESCENT; ADULT; ANTIGENS, CD; ANTIGENS, CD4; ANTIGENS, CD8; CARRIER PROTEINS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DNA, VIRAL; FEMALE; GLYCOPROTEINS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOGLOBULINS; INFECTIOUS MONONUCLEOSIS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOCYTE ACTIVATION; MALE; MEMBRANE GLYCOPROTEINS; PHARYNGITIS; RECEPTORS, CELL SURFACE; RECEPTORS, IMMUNOLOGIC; SEVERITY OF ILLNESS INDEX; UP-REGULATION;

EID: 3042802287     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/421276     Document Type: Article

References (38)

1. Sawyer RN, Evans AS, Niederman JC, McCollum RW. Prospective studies of a group of Yale University freshmen. I. Occurrence of infectious mononucleosis. J Infect Dis 1971; 123:263-70.
2. Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000; 343:481-92.
3. + T cells in acute infectious mononucleosis. Nat Med 1996; 2:906-11.
4. Foss H-D, Herbst H, Hummel M, et al. Patterns of cytokine gene expression in infectious mononucleosis. Blood 1994; 83:707-12.
5. Andersson J. Clinical and immunological considerations in Epstein-Barr virus-associated diseases. Scand J Infect Dis Suppl 1996; 100:72-82.
6. Biglino A, Sinicco A, Forno B, et al. Serum cytokine profiles in acute primary HIV-1 infection and in infectious mononucleosis. Clin Immunol Immunopathol 1996; 78:61-9.
7. Miyashita EM, Yang B, Babcock GJ, Thorley-Lawson DA. Identification of the site of Epstein-Barr virus persistence in vivo as a resting B cell. J Virol 1997; 71:4882-91.
8. Fleisher G, Henle W, Henle G, Lennette ET, Biggar RJ. Primary infection with Epstein-Barr virus in infants in the United States: clinical and serologic observations. J Infect Dis 1979; 139:553-8.
9. University Health Physicians and Public Health Laboratory Service Laboratories. Infectious mononucleosis and its relationship to EB virus antibody. Brit Med J 1971; 4:643-6.
10. Hallee TJ, Evans AS, Niederman JC, Brooks CM, Voegtly JH. Infectious mononucleosis at the United States Military Academy: a prospective study of a single class over four years. Yale J Biol Med 1974; 47:182-95.
11. Niederman JC, Evans A, Subrahmanyan C, McCollum RW. Prevalence, incidence and persistence of EB virus antibodies in young adults. N Engl J Med 1970; 282:361-5.
12. Purtilo DT, Cassel CK, Yang JPS, Harper R. X-linked recessive progressive combined variable immunodeficiency (Duncan's disease). Lancet 1975; 1:935-40.
13. Hamilton JK, Paquin LA, Sullivan JL, et al. X-linked lymphoproliferative syndrome registry report. J Pediatr 1980; 96:669-73.
14. Sayos J, Wu C, Morra M, et al. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature 1998; 395:462-9.
15. Coffey AJ, Brooksbank RA, Brandau O, et al. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat Genet 1998; 20:129-35.
16. Nichols KE, Harkin DP, Levitz S, et al. Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. Proc Natl Acad Sci USA 1998; 95:13765-70.
17. Tangye SG, Phillips JH, Lanier LL, Nichols KE. Functional requirement for SAP in CD244-mediated activation of human natural killer cells as revealed by the X-linked lymphoproliferative syndrome. J Immunol 2000; 165:2932-6.
18. Tangye SG, Lazetic S, Woollatt E, Sutherland GR, Lanier LL, Phillips JH. Human CD244, an activating NK cell receptor, recruits the protein tyrosine phosphatase SHP-2 and the adaptor signaling protein SAP. J Immunol 1999; 162:6981-5.
19. Aoukaty A, Tan R. Association of the XLP gene product SAP/SH2D1A with CD244, a natural killer cell activating molecule, is dependent on phosphoinositide 3-kinase. J Biol Chem 2002; 277:13331-7.
20. Latour S, Gish G, Helgason CD, Humphries RK, Pawson T, Veillette A. Regulation of SLAM-mediated signal transduction by SAP, the X-linked lymphoproliferative gene product. Nat Immunol 2001; 2:681-90.
21. Sayos J, Martin M, Chen A, et al. Cell surface receptors LY-9 and CD84 recruit the X-linked lymphoproliferative disease gene product SAP. Blood 2001; 97:3867-74.
22. Cocks BG, Chang CC-J, Carballido JM, Yssel H, de Vries JE, Aversa G. A novel receptor involved in T-cell activation. Nature 1995; 376:260-3.
23. Aversa G, Carballido J, Punnonen J, et al. SLAM and its role in T cell activation and Th cell responses. Immunol Cell Biol 1997; 75:202-5.
24. Latchman Y, McKay PF, Reiser H. Identification of the CD244 molecule as a counter-receptor for CD48. J Immunol 1998; 161:5809-12.
25. Chuang SS, Kumaresan PR, Mathew PA. 2B4 (CD244)-mediated activation of cytotoxicity and IFN-gamma release in human NK cells involves distinct pathways. J Immunol 2001; 167:6210-6.
26. Nakajima H, Cella M, Langen H, Friedlein A, Colonna M. Activating interactions in human NK cell recognition: the role of CD244-CD48. Eur J Immunol 1999; 29:1676-83.
27. Wu C, Nguyen KB, Pien GC, et al. SAP controls T cell responses to virus and terminal differentiation of Th2 cells. Nat Immunol 2001; 2:410-4.
28. Czar MJ, Kersh EN, Mijares LA, et al. Altered lymphocyte responses and cytokine production in mice deficient in the X-linked lymphoproliferative disease gene SH2D1A/DSHP/SAP. Proc Natl Acad Sci USA 2001; 98:7449-54.
29. Stevens SJC, Vervoort MBHJ, Van Den Brule AJC, Meenhorst PL, Meijer CJ, Middeldorp JM. Monitoring of Epstein-Barr virus DNA load in peripheral blood by quantitative competitive PCR. J Clin Microbiol 1999; 37:2852-7.
30. Crawford DH, Brickell P, Tidman N, McConnell I, Hoffbrand AV, Janossy G. Increased numbers of cells with suppressor T cell phenotype in the peripheral blood of patients with infectious mononucleosis. Clin Exp Immunol 1981; 43:291-7.
31. Tomkinson BE, Wagner DK, Nelson DL, Sullivan JL. Activated lymphocytes during acute Epstein-Barr virus infection. J Immunol 1987; 139:3802-7.
32. Dong C, Flavell RA. Th1 and Th2 cells. Curr Opin Hematol 2001; 8: 47-51.
33. Hwang PM, Li C, Morra M, et al. A "three-pronged" binding mechanism for the SAP/SH2D1A SH2 domain: structural basis and relevance to the XLP syndrome. EMBO J 2002; 21:314-23.
34. Arvin AA. Varicella zoster virus. In: Fields BN, Knipe DM, Howley PM, eds. Fields virology. 3rd ed. Philadelphia: Lippincott-Raven, 1996: 2547.
35. Robinson J, Smith D, Niederman J. Mitotic EBNA-positive lymphocytes in peripheral blood during infectious mononucleosis. Nature 1980; 287:334-5.
36. Crawford DH, Swerdlow AJ, Higgins C, et al. Sexual history and Epstein-Barr virus infection. J Infect Dis 2002; 186:731-6.
37. Epstein MA, Crawford DH. Epstein-Barr virus. In: Weatherall DJ, Ledingham JGG, Warrell DA, eds. The Oxford textbook of medicine. 3rd ed. Oxford: Oxford University Press, 1996:352-6.
38. Silins SL, Sherritt MA, Silleri JM, et al. Asymptomatic primary Epstein-Barr virus infection occurs in the absence of blood T-cell repertoire perturbations despite high levels of systemic viral load. Blood 2001; 98:3739-44.